Trial · NCT00205777
Results by group619
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 619
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With New Vertebral Fractures Through Month 36 | Bazedoxifene 20 mg (Core+SE I) | No Prevalent Fracture (n=757,744,742,760) | 1.98 | 95% Confidence Interval 1.15 to 3.40 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 36 | Bazedoxifene 40 mg (Core) | No Prevalent Fracture (n=757,744,742,760) | 2.14 | 95% Confidence Interval 1.25 to 3.67 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 36 | Raloxifene 60 mg (Core) | No Prevalent Fracture (n=757,744,742,760) | 1.84 | 95% Confidence Interval 1.04 to 3.22 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 36 | Placebo (Core+SE I+SE II) | No Prevalent Fracture (n=757,744,742,760) | 3.13 | 95% Confidence Interval 2.03 to 4.82 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 36 | Bazedoxifene 20 mg (Core+SE I) | At Least 1 Prevalent Fracture (n=967,942,954,981) | 2.63 | 95% Confidence Interval 1.73 to 3.98 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 36 | Bazedoxifene 40 mg (Core) | At Least 1 Prevalent Fracture (n=967,942,954,981) | 2.80 | 95% Confidence Interval 1.86 to 4.20 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 36 | Raloxifene 60 mg (Core) | At Least 1 Prevalent Fracture (n=967,942,954,981) | 2.74 | 95% Confidence Interval 1.81 to 4.14 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 36 | Placebo (Core+SE I+SE II) | At Least 1 Prevalent Fracture (n=967,942,954,981) | 4.80 | 95% Confidence Interval 3.52 to 6.52 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 60 | Bazedoxifene 20 mg (Core+SE I) | No Prevalent Fracture (n=757,760,744) | 3.11 | 95% Confidence Interval 1.94 to 4.96 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 60 | Placebo (Core+SE I+SE II) | No Prevalent Fracture (n=757,760,744) | 5.40 | 95% Confidence Interval 3.73 to 7.80 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 60 | Bazedoxifene 40/20 mg (SE I) | No Prevalent Fracture (n=757,760,744) | 3.46 | 95% Confidence Interval 2.20 to 5.43 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 60 | Bazedoxifene 20 mg (Core+SE I) | At Least 1 Prevalent Fracture (n=967,981,942) | 5.67 | 95% Confidence Interval 4.05 to 7.92 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 60 | Placebo (Core+SE I+SE II) | At Least 1 Prevalent Fracture (n=967,981,942) | 7.95 | 95% Confidence Interval 6.07 to 10.37 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 60 | Bazedoxifene 40/20 mg (SE I) | At Least 1 Prevalent Fracture (n=967,981,942) | 4.28 | 95% Confidence Interval 2.97 to 6.17 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 84 | Placebo (Core+SE I+SE II) | No Prevalent Fracture (n=760,1501) | 8.18 | 95% Confidence Interval 5.73 to 11.61 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 84 | Bazedoxifene 20 mg (SE II) | No Prevalent Fracture (n=760,1501) | 5.79 | 95% Confidence Interval 4.24 to 7.89 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 84 | Placebo (Core+SE I+SE II) | At Least 1 Prevalent Fracture (n=981,1909) | 11.35 | 95% Confidence Interval 8.63 to 14.86 | Percentage of participants |
| Percentage of Participants With New Vertebral Fractures Through Month 84 | Bazedoxifene 20 mg (SE II) | At Least 1 Prevalent Fracture (n=981,1909) | 6.90 | 95% Confidence Interval 5.32 to 8.92 | Percentage of participants |
| Incidence of Breast Cancer Through Month 36 | Bazedoxifene 20 mg (Core+SE I) | 1.09 | Breast cancer per 1000-women years | ||
| Incidence of Breast Cancer Through Month 36 | Bazedoxifene 40 mg (Core) | 0.90 | Breast cancer per 1000-women years |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00205777/results